HK1127301A1 - Jak inhibitors for treatment of myeloproliferative disorders - Google Patents

Jak inhibitors for treatment of myeloproliferative disorders

Info

Publication number
HK1127301A1
HK1127301A1 HK09107276.1A HK09107276A HK1127301A1 HK 1127301 A1 HK1127301 A1 HK 1127301A1 HK 09107276 A HK09107276 A HK 09107276A HK 1127301 A1 HK1127301 A1 HK 1127301A1
Authority
HK
Hong Kong
Prior art keywords
treatment
myeloproliferative disorders
jak inhibitors
jak
inhibitors
Prior art date
Application number
HK09107276.1A
Other languages
English (en)
Inventor
Pawel Dobrzanski
Bruce A Ruggeri
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1127301A1 publication Critical patent/HK1127301A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK09107276.1A 2006-07-21 2009-08-07 Jak inhibitors for treatment of myeloproliferative disorders HK1127301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83262706P 2006-07-21 2006-07-21
US11/880,063 US20080021013A1 (en) 2006-07-21 2007-07-19 JAK inhibitors for treatment of myeloproliferative disorders
PCT/US2007/016513 WO2008011174A2 (en) 2006-07-21 2007-07-20 Jak inhibitors for treatment of myeloproliferative disorders

Publications (1)

Publication Number Publication Date
HK1127301A1 true HK1127301A1 (en) 2009-09-25

Family

ID=38814536

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09107276.1A HK1127301A1 (en) 2006-07-21 2009-08-07 Jak inhibitors for treatment of myeloproliferative disorders

Country Status (14)

Country Link
US (1) US20080021013A1 (xx)
EP (1) EP2046340B1 (xx)
JP (1) JP5340931B2 (xx)
KR (1) KR101399180B1 (xx)
AU (1) AU2007275562B2 (xx)
BR (1) BRPI0715196A2 (xx)
CA (1) CA2658192C (xx)
ES (1) ES2437317T3 (xx)
HK (1) HK1127301A1 (xx)
IL (1) IL196517A (xx)
MX (1) MX2009000713A (xx)
NO (1) NO20090415L (xx)
NZ (1) NZ574212A (xx)
WO (1) WO2008011174A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8460240B2 (en) * 2006-08-07 2013-06-11 W. L. Gore & Associates, Inc. Inflatable toroidal-shaped balloons
US20080125711A1 (en) * 2006-08-07 2008-05-29 Alpini Alfred A Catheter balloons with integrated non-distensible seals
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
BR112014013224B1 (pt) 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
MA45504B1 (fr) 2012-12-07 2021-10-29 Geron Corp Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
CA3211748A1 (en) * 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303697B1 (en) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
EP0699204B1 (en) * 1993-05-28 1998-04-15 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
EP1011648B2 (en) * 1997-08-15 2005-07-20 Cephalon, Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
ES2194385T3 (es) * 1997-12-31 2003-11-16 Cephalon Inc Derivados del k-252a 3'-epimeros.
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US20040246627A1 (en) * 2003-06-06 2004-12-09 Durrum Thomas M. Disc drive pivot bearing assembly
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20060281700A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
ES2390135T3 (es) * 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
WO2007070444A1 (en) * 2005-12-09 2007-06-21 Abbott Laboratories Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib

Also Published As

Publication number Publication date
AU2007275562A1 (en) 2008-01-24
KR101399180B1 (ko) 2014-05-27
EP2046340A2 (en) 2009-04-15
BRPI0715196A2 (pt) 2013-11-12
ES2437317T3 (es) 2014-01-10
JP2009544700A (ja) 2009-12-17
NO20090415L (no) 2009-02-20
KR20090035596A (ko) 2009-04-09
AU2007275562B2 (en) 2013-10-31
WO2008011174A3 (en) 2008-03-06
IL196517A (en) 2015-08-31
MX2009000713A (es) 2009-03-04
JP5340931B2 (ja) 2013-11-13
WO2008011174A2 (en) 2008-01-24
US20080021013A1 (en) 2008-01-24
CA2658192C (en) 2016-05-24
EP2046340B1 (en) 2013-09-04
IL196517A0 (en) 2009-11-18
CA2658192A1 (en) 2008-01-24
NZ574212A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
HK1127301A1 (en) Jak inhibitors for treatment of myeloproliferative disorders
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
GB0610867D0 (en) Treatment of pain
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
IL193748A0 (en) Treatment of pain
GB0703909D0 (en) Treatment of anxiety disorders
EP2032131A4 (en) Methods of Treatment
IL193747A0 (en) New therapeutic combinations for the treatment of depression
HK1247943A1 (zh) 發育相關疾病的治療
IL222557A (en) A compound for use in treating mutant disorders has ruled
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
GB0610746D0 (en) Method of treatment
PL2061501T3 (pl) Sposób leczenia zaburzeń oddechowych
EP2120930A4 (en) USE OF CHROMIHISTIDINATE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
ZA201000225B (en) Treatment of depression
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0610868D0 (en) Treatment of pain
EP2328584A4 (en) TREATMENT OF NEUROLOGICAL DISORDERS USING HUPERZINE
EP2037943A4 (en) TREATMENT OF BIND WEB DISEASES
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
EP2212246B1 (en) TREATMENT OF NEUROLOGICAL DISORDERS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170720